Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Paul Johns
Trade Marks

Green light for patent reform in Australia

by | Aug 25, 2017

This afternoon, the Australian Government released its response to the report of the Productivity Commission Inquiry into IP released 20 December 2016.

In its 25 page response to the 752 page Productivity Commission report, the Government has agreed to the following patent reform initiatives:

  • Australia will further “raise the bar” for the standard of obviousness, by
    • adding an “objects” clause into the Patents Act to provide a clear statement of intent and guidance to the Courts in interpreting the Act; and
    • amending the statutory test for inventive step (and corresponding Patent Office Manual) to ensure that a “scintilla of invention” is not enough for inventive step.
  • The Innovation patent system will be abolished.

The Government has also confirmed the following:

  • There will be no immediate change to patent term extensions in Australia.
  • Reporting obligations regarding settlements for “pay for delay” analysis by ACCC are coming.
  • No guiding principles to be developed for International Trade Agreements;
  • No low cost/fast track IP list in the Federal Circuit Court.

Interestingly, despite the Productivity Commission recommendations supporting the inclusion of provisions supporting Manufacture for Export (MFE) (manufacture during patent term extension for export purposes only) in international trade agreements, the Government response did not mention MFE.  The Government noted the relevant recommendation, and commented on its active engagement in international IP forums, without further substantive comment about MFE.

Most of these patent reform initiatives have been discussed in multiple Inquiries in the past 5 years (including the 2012 Raising the Bar initiative, 2013 Pharmaceutical Patent Review, 2015 ACIP Innovation patent system review), and it is exciting to see some traction from the Australian government in its response to the Productivity Commission Report.

The most significant changes for the biopharma/pharma industries are those relating to obviousness, extensions of term, and MFE, and both generic/biosimilar companies and originator companies will have something to celebrate in the proposed law reform package.  Generic/biosimilar companies will be glad for the further increases in the standards for obviousness in Australia, bringing Australia more closely into line with the position in Europe.  Originators will be glad that the patent term extension and MFE debates are saved for another day.

Naomi Pearce

Naomi Pearce

CEO, Executive Lawyer (AU, NZ), Patent & Trade Mark Attorney (AU, NZ)

Naomi is the founder of Pearce IP, and is one of Australia’s leading IP practitioners.   Naomi is a market leading, strategic, commercially astute, patent lawyer, patent attorney and trade mark attorney, with over 25 years’ experience, and a background in molecular biology/biochemistry.  Ranked in virtually every notable legal directory, highly regarded by peers and clients, with a background in molecular biology, Naomi is renown for her successful and elegant IP/legal strategies.

Among other awards, Naomi is ranked in Chambers, IAM Patent 1000, IAM Strategy 300, is a MIP “Patent Star”, and is recognised as a WIPR Leader for patents and trade marks. Naomi is the 2023 Lawyers Weekly “IP Partner of the Year”, the 2022 Lexology client choice award recipient for Life Sciences, the 2022 Asia Pacific Women in Business Law “Patent Lawyer of the Year” and the 2021 Lawyers Weekly Women in Law SME “Partner of the Year”.  Naomi is the founder of Pearce IP, which commenced in 2017 and won 2021 “IP Team of the Year” at the Australian Law Awards.

Get our Pearce IP Blogs & BioBlast® sent directly to your inbox

Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.

Our Latest News